“General Hospital” character Anna Devane ponders her diagnosis. Polycythemia vera is an uncommon blood cancer that can be controlled with long-established treatments. So it seemed more than a little suspicious to Vinay Prasad, M.D., M.P.H., when the disease took center stage in an episode of “General Hospital” – the longest running daytime drama on American television. “I felt there had to be some backstory,” Prasad, an OHSU Knight Cancer Institute hematologist-oncologist told listeners of the public radio … Read More
Posts Tagged ‘Food and Drug Administration’
When reviewers with the Food and Drug Administration weigh the evidence for a drug company’s experimental treatment, how many are thinking: I may someday work for that company? It’s a difficult question to answer but research by two OHSU physicians provides some of the first hard data.
Among 55 cancer drugs recently approved on the basis of a surrogate endpoint, less than one-fifth have been shown to improve survival in follow-up clinical trials. Fully two-thirds of new cancer drugs in recent years gained regulatory approval based on a so-called surrogate end point, such as tumor shrinkage, rather than a clinical end point directly measuring how patients feel, how well they function or how long they survive. This shortcut strategy makes sense … Read More